Edited by
Hiroshi Kase, Kyowa Hakko Kogyo Co., Ltd., Tokyo, Japan
Peter Richardson, University of Cambridge, U.K.
Peter Jenner, King's College, London, U.K.
Description
This book is the first definitive overview on adenosine receptor antagonists and their application to the treatment of Parkinson's Disease.
The effect of these novel non-dopamine drugs on
vitro and
in vivo systems clearly shows their potential for the treatment
of this debilitating disease. This book covers how the Parkinson's disease antagonist drug, A2A, has been researched, developed, and
tested. It is an essential book for researchers interested in the basal ganglia, purine biology, and Parkinson's Disease.
Audience:
Neuroscientists, neurologists, pharmacologists, biochemists, and geneticists, especially all workers in the basal ganglia, purine, and Parkinson's fields.
